Peptide Receptor Radionuclide Therapy (177Lu-DOTA Therapy), formally, is a targeted radiation treatment of neuroendocrine tumours whose spread has extended beyond its location.  

These tumours could develop in the gastrointestinal tract, pancreas, lungs, or thymus, and it is usually difficult to treat when they are advanced. As an effective and focused intervention, 177Lu-DOTA therapy is very successful in patients with incurable, inoperable, or metastatic NETs.  

This is a treatment that employs the radioactive isotope Lutetium -177 in conjunction with a somatostatin analogue, e.g.:  

• DOTA‑TATE  
• DOTA‑TOC  
• DOTA‑NOC  

Those compounds pass to somatostatin receptors (SSTR) concentrated in significant numbers on many neuroendocrine tumour cells, allowing the radiation to reach the tumour, sparing normal tissue.  

Important Note on Dosage

This is a 200 mCi package, but the typical amount of each dose is approximately 100-200 mCi (3.7-7.4GBq), and therapy is administered three to five cycles.  

The dose varies depending on the weight, condition, kidney, bone marrow functionstumouror burden, and response of the patient. The nuclear medicine specialist in charge of administration determines the ultimate dose and dose schedule.  

What is PRRT and How Does it Work?

PRRT is a cancer treatment method that uses radioactive therapy to destroy cellular tumours by incorporating the somatostatin analogue with Lutetium-177.  

Mechanism:  

• The presence of SSTRs in the tumour cells should be verified by a 68Ga -DOTA PET-CT scan. 
• Introduce the 177Lu 0 DOTA IV.  
• The compound is associated with tumour cell receptors.  
• It emits beta radiation.  
• The radiation breaks the DNA of tumours, killing or halting the growth of cells.  

This results in the shrinkage or stabilisation of the tumours with minimal tissue effect.

Common Indications for 177Lu-DOTA Therapy

• Usual Capabilities of 177Lu-DOTA Therapy.  
• Well-differentiated metastatic neuroendocrine tumours.  
• Confirmed PET-CT tumors SSTR- positive.  
• Pancreatic, gastrointestinal, bronchial, or thymic NETs.  
• Progressive or Inoperable Disease.  
• Necrosis following previous procedures.  

Treatment Process

1. Pre-Therapy Evaluation

• Perform a 68Ga‑DOTA PET‑CT scan.  
• Examine kidney and liver functioning.  
• Perform a complete blood count (CBC).  
• Tumour markers include Chromogranin A.  
• Check the history of clinical and past treatments of that particular patient.

2. Administration of Therapy

• Administer the treatment through intravenous infusion for 30-60 minutes.  
• Add amino acids to take care of the kidneys.  
• Measure vital signs when infusing.  
• Observe radiation safety measures.  
• The majority of patients were discharged from the hospital within 24 hours.  

3. Treatment Schedule

• Deliver 3 to 5 cycles of therapy.  
• Space each cycle 6‑12 weeks apart.  
• Ahead of the set of restrictions, do interim imaging and blood tests.  

Benefits of 177Lu-DOTA Therapy

• It is very specific to the treatment.  
• It results in minimal damage to normal tissues.  
• It enhances the signs of flushing, diarrhea, and stomachache.  
• It impairs the development of the tumour.  
• It enhances progression-free survival.  
• For patients who could not tolerate chemotherapy, it is appropriate.  
• It is safe to repeat it in specific patients.  

Potential Side Effects

As a rule, well tolerated, but might encompass:  

• Mild nausea and fatigue.  
• Temporary reduction in the number of blood cells, such as anaemia or low platelets.  
• Dry mouth or a metallic taste.  
• Light abdominal discomfort.  

Less Common Risks:  

• Reduced kidney problems caused by amino acid infusion.  
• Bone marrow suppression.  
• Rare liver toxicity.  
• The majority of the side effects are short-lived and can be managed.  

Who is Not a Candidate?

The therapy is not perhaps appropriate for patients who have:  

• Severe kidney dysfunction.  
• Poor bone marrow reserve.  
• SSTR- negative tumour (negative PET -CT).  
• Severe liver impairment.  
• Women who are pregnant or those who are breastfeeding.  

Monitoring Treatment Response

After each cycle:  

• Evaluate whether the symptoms have improved.  
• Measure tumour markers, e.g., Chromogranin A.  
• Carry out imaging using PET-CT or MRI.  
• Conduct blood tests to determine the functionality of organs.  

Determine other cycles depending on the response and tolerance of the patient to treatment. 

Conclusion

177Lu -DOTA Therapy 200 mc - An intense and locally administered therapy of an advanced neuroendocrine tumour.  

It hits the somatostatin receptors, thereby providing cancer cells with radiation and sparing other parts of the body.  

It assists in managing tumoral growth, enhances symptoms, and increases the quality of life.  

Having an excellent safety profile and with positive clinical outcomes, PRRT is currently a universal standard therapy against metastatic NETs.  

Patients diagnosed with neuroendocrine tumours are advised to discuss 177Lu‑DOTA Therapy with a nuclear medicine specialist to identify whether a patient suits the efficacy of 177Lu Therapy or not.